^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CLDN6 inhibitor

    Related drugs:
    1m
    CNTX-CTIM76-101: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=80, Recruiting, Context Therapeutics Inc. | Trial primary completion date: Jul 2027 --> Apr 2027
    Trial primary completion date • First-in-human
    |
    CTIM-76
    5ms
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=231, Active, not recruiting, Chugai Pharmaceutical | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN6 (Claudin 6)
    |
    SAIL66
    6ms
    XmAb541-01: Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=212, Recruiting, Xencor, Inc. | Completed --> Recruiting | N=60 --> 212 | Trial completion date: May 2025 --> Dec 2028 | Trial primary completion date: May 2025 --> Dec 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    6ms
    XmAb541-01: Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Completed, Xencor, Inc. | Recruiting --> Completed | N=212 --> 60 | Trial completion date: Dec 2028 --> May 2025 | Trial primary completion date: Dec 2027 --> May 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    7ms
    Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=73, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting | N=330 --> 73 | Trial completion date: Apr 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    CLDN6 (Claudin 6)
    |
    BNT142
    10ms
    A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=80, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    10ms
    A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
    P1, N=3, Terminated, Amgen | Trial completion date: Dec 2023 --> Apr 2024
    Trial completion date
    |
    CLDN6 (Claudin 6)
    |
    AMG 794
    12ms
    177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer. (PubMed, J Nucl Med)
    The radiotracer [89Zr]Zr-DFO-IMAB027 showed high contrast when visualizing CLDN6-expressing xenografts for PET imaging, and [177Lu]Lu-DOTA-IMAB027 induced rapid tumor regression in both the TE-1-CLDN6 and the CLDN6-PDX models. This research has implications for improving the radioligand diagnosis and treatment of EC.
    Journal
    |
    CLDN6 (Claudin 6)
    |
    ASP1650
    12ms
    A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=80, Not yet recruiting, BeiGene
    New P1 trial
    1year
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=231, Recruiting, Chugai Pharmaceutical | Trial completion date: Dec 2028 --> Oct 2029 | Trial primary completion date: Dec 2028 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    CLDN6 (Claudin 6)
    |
    Gazyva (obinutuzumab) • SAIL66
    1year
    A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Astellas Pharma Global Development, Inc. | N=197 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    over1year
    SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137. (PubMed, J Immunother Cancer)
    Our data demonstrate that SAIL66, designed to engage CLDN6, CD3, and CD137, has the potential to enhance antitumor activity and provide a potent therapeutic option for patients with ovarian and other solid tumors expressing CLDN6. Clinical trials are currently underway to evaluate the safety and efficacy of SAIL66.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CLDN6 (Claudin 6) • CD4 (CD4 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CLDN6 expression • CLDN6 positive
    |
    SAIL66